Neurolief

Company Overview

Snapshot

Founded in August 2013 by Amit Dar, Neurolief operates with 11–50 employees. The company has raised $17.05M across 4 funding rounds from 5 investors. In January 2026, Neurolief received FDA PMA approval for its at-home brain neuromodulation therapy for depression.

Business overview

Neurolief is a Health Tech & Life Sciences company focused on developing treatments for chronic neurological and neuropsychiatric disorders. The company's core product, Relivion, is a noninvasive multichannel brain neuromodulation system that delivers precise, personalized care by stimulating occipital and trigeminal nerves. This digital therapeutics platform is designed for at-home or community use, modulating brain networks associated with pain and mood control. Neurolief serves patients and healthcare providers in markets including the United States, China, Japan, South Korea, and Europe, operating within the Digital Therapeutics sector.

Strategic signal

In August 2026, Neurolief expanded veterans' access to its prescription neuromodulation therapies for depression and migraine through a new VA contract. This strategic move signals the company's commitment to broadening market access and securing significant contracts within the healthcare system, indicating strong commercial traction and potential for wider adoption of its digital therapeutic solutions.

Company Intelligence Q&A

What was a key regulatory achievement for Neurolief in early 2026?

In January 2026, Neurolief received FDA PMA approval for its at-home brain neuromodulation therapy, specifically for adults whose depression had not adequately improved with antidepressants.

What strategic partnership did Neurolief secure in August 2026?

In August 2026, Neurolief expanded veterans' access to its prescription neuromodulation therapies for depression and migraine through a new contract with the VA.

What significant clinical study results did Neurolief present in October 2024?

In October 2024, Neurolief presented groundbreaking study results for its ProlivRx brain neuromodulation therapy for treating major depression at the 7th Annual Neuropsychiatric Drug Summit.

Who was appointed as Neurolief's Chief Medical Officer in February 2025?

In February 2025, Neurolief appointed Dr. Owen Muir as Chief Medical Officer to drive innovation in depression treatment.

Which company made a strategic investment in Neurolief in August 2025?

In August 2025, Brainsway made a strategic investment in Neurolief to expand its total addressable market through neuromodulation systems for mental health care.